Mpm Bioimpact
$1.6B 13F equity value
48 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Mpm Bioimpact covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | 9,731,341 | $177M | 10.8% |
| AKTS | Aktis Oncology, Inc. | 4,835,872 | $156M | 9.5% |
| LQDA | Liquidia Corporation | 1,386,174 | $111M | 6.7% |
| RVMD | Revolution Medicines, Inc. | 492,483 | $92M | 5.6% |
| CORT | Corcept Therapeutics, Inc. | 771,028 | $67M | 4.1% |
| EWTX | Edgewise Therapeutics Inc | 1,620,780 | $66M | 4.0% |
| TVTX | Travere Therapeutics Inc | 1,122,731 | $64M | 3.9% |
| DBVT | DBV Technologies S A | 3,666,284 | $60M | 3.7% |
| TRVI | Trevi Therapeutics Inc | 3,073,577 | $57M | 3.5% |
| ALMS | Alumis Inc | 2,019,020 | $57M | 3.5% |
Track Mpm Bioimpact's 13F portfolio: $1.6B in reported holdings, 48 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}